<?xml version='1.0' encoding='utf-8'?>
<document id="29748935"><sentence text="Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers."><entity charOffset="65-75" id="DDI-PubMed.29748935.s1.e0" text="Rifampicin" /></sentence><sentence text="To evaluate association of the dose-dependent effect of rifampicin, an OATP1B inhibitor, on the plasma concentration-time profiles among OATP1B substrates drugs and endogenous substrates"><entity charOffset="56-66" id="DDI-PubMed.29748935.s2.e0" text="rifampicin" /></sentence><sentence text="" /><sentence text="Eight healthy volunteers received atorvastatin (1 mg), pitavastatin (0"><entity charOffset="34-46" id="DDI-PubMed.29748935.s4.e0" text="atorvastatin" /><entity charOffset="55-67" id="DDI-PubMed.29748935.s4.e1" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.29748935.s4.e0" e2="DDI-PubMed.29748935.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s4.e0" e2="DDI-PubMed.29748935.s4.e1" /></sentence><sentence text="2 mg), rosuvastatin (0"><entity charOffset="7-19" id="DDI-PubMed.29748935.s5.e0" text="rosuvastatin" /></sentence><sentence text="5 mg), and fluvastatin (2 mg) alone or with rifampicin (300 or 600 mg) in a crossover fashion"><entity charOffset="11-22" id="DDI-PubMed.29748935.s6.e0" text="fluvastatin" /><entity charOffset="44-54" id="DDI-PubMed.29748935.s6.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29748935.s6.e0" e2="DDI-PubMed.29748935.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s6.e0" e2="DDI-PubMed.29748935.s6.e1" /></sentence><sentence text=" The plasma concentrations of these OATP1B probe drugs, total and direct bilirubin, glycochenodeoxycholate-3-sulfate (GCDCA-S), and coproporphyrin I, were determined"><entity charOffset="73-82" id="DDI-PubMed.29748935.s7.e0" text="bilirubin" /><entity charOffset="84-116" id="DDI-PubMed.29748935.s7.e1" text="glycochenodeoxycholate-3-sulfate" /><entity charOffset="118-125" id="DDI-PubMed.29748935.s7.e2" text="GCDCA-S" /><entity charOffset="132-148" id="DDI-PubMed.29748935.s7.e3" text="coproporphyrin I" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e0" e2="DDI-PubMed.29748935.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e0" e2="DDI-PubMed.29748935.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e0" e2="DDI-PubMed.29748935.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e0" e2="DDI-PubMed.29748935.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e1" e2="DDI-PubMed.29748935.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e1" e2="DDI-PubMed.29748935.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e1" e2="DDI-PubMed.29748935.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e2" e2="DDI-PubMed.29748935.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29748935.s7.e2" e2="DDI-PubMed.29748935.s7.e3" /></sentence><sentence text="" /><sentence text="The most striking effect of 600 mg rifampicin was on atorvastatin (6"><entity charOffset="35-45" id="DDI-PubMed.29748935.s9.e0" text="rifampicin" /><entity charOffset="53-65" id="DDI-PubMed.29748935.s9.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29748935.s9.e0" e2="DDI-PubMed.29748935.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s9.e0" e2="DDI-PubMed.29748935.s9.e1" /></sentence><sentence text="0-times increase) and GCDCA-S (10-times increase)" /><sentence text=" The AUC0-24h of atorvastatin was reasonably correlated with that of pitavastatin (r2 = 0"><entity charOffset="17-29" id="DDI-PubMed.29748935.s11.e0" text="atorvastatin" /><entity charOffset="69-81" id="DDI-PubMed.29748935.s11.e1" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.29748935.s11.e0" e2="DDI-PubMed.29748935.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s11.e0" e2="DDI-PubMed.29748935.s11.e1" /></sentence><sentence text="73) and with the AUC0-4h of fluvastatin (r2 = 0"><entity charOffset="28-39" id="DDI-PubMed.29748935.s12.e0" text="fluvastatin" /></sentence><sentence text="62) and sufficiently with the AUC0-24h of rosuvastatin (r2 = 0"><entity charOffset="42-54" id="DDI-PubMed.29748935.s13.e0" text="rosuvastatin" /></sentence><sentence text="32)" /><sentence text=" The AUC0-24h of GCDCA-S was reasonably correlated with those of direct bilirubin (r2 = 0"><entity charOffset="72-81" id="DDI-PubMed.29748935.s15.e0" text="bilirubin" /></sentence><sentence text="74) and coproporphyrin I (r2 = 0" /><sentence text="78), and sufficiently with that of total bilirubin (r2 = 0"><entity charOffset="41-50" id="DDI-PubMed.29748935.s17.e0" text="bilirubin" /></sentence><sentence text="30)" /><sentence text=" The AUC0-24h of GCDCA-S, direct bilirubin, and coproporphyrin I were reasonably correlated with that of atorvastatin (r2 = 0"><entity charOffset="33-42" id="DDI-PubMed.29748935.s19.e0" text="bilirubin" /><entity charOffset="48-64" id="DDI-PubMed.29748935.s19.e1" text="coproporphyrin I" /><entity charOffset="105-117" id="DDI-PubMed.29748935.s19.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29748935.s19.e0" e2="DDI-PubMed.29748935.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s19.e0" e2="DDI-PubMed.29748935.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s19.e0" e2="DDI-PubMed.29748935.s19.e2" /><pair ddi="false" e1="DDI-PubMed.29748935.s19.e1" e2="DDI-PubMed.29748935.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s19.e1" e2="DDI-PubMed.29748935.s19.e2" /></sentence><sentence text="48-0" /><sentence text="70) [corrected]" /><sentence text="" /><sentence text="These results suggest that direct bilirubin, GCDCA-S, and coproporphyrin I are promising surrogate probes for the quantitative assessment of potential OATP1B-mediated DDI"><entity charOffset="34-43" id="DDI-PubMed.29748935.s23.e0" text="bilirubin" /><entity charOffset="45-52" id="DDI-PubMed.29748935.s23.e1" text="GCDCA-S" /><entity charOffset="58-74" id="DDI-PubMed.29748935.s23.e2" text="coproporphyrin I" /><pair ddi="false" e1="DDI-PubMed.29748935.s23.e0" e2="DDI-PubMed.29748935.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29748935.s23.e0" e2="DDI-PubMed.29748935.s23.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s23.e0" e2="DDI-PubMed.29748935.s23.e2" /><pair ddi="false" e1="DDI-PubMed.29748935.s23.e1" e2="DDI-PubMed.29748935.s23.e1" /><pair ddi="false" e1="DDI-PubMed.29748935.s23.e1" e2="DDI-PubMed.29748935.s23.e2" /></sentence><sentence text="" /></document>